iZafe Group (IZAFE-B) Fair Value & Analysis
Healthcare · SE · Market cap 155M SEK
Fair value as of: Jul 12, 2026
From 1 valuation models · updated 9 days ago
Share price −11.9% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 0.2960 – kr 0.7220 · fair‑value band kr 0.0850 – kr 0.2465 · the kr 0.3630 price screens above the kr 0.1615 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
iZafe Group (IZAFE-B) currently trades at kr 0.3630, while our model-based Fair Value estimate is kr 0.1615, implying the stock looks roughly 55.5% overvalued today. We read business quality at 23/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 7.1M SEK. Revenue grew 83.5% year over year. The balance sheet holds a net cash position of 1.6M SEK. Fundamentals as of Jul 12, 2026
Our scenario range runs from kr 0.0850 (bear case) to kr 0.2465 (bull case); at kr 0.3630, the current price sits above that range. The share trades about 55% below its 52-week high and 58% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at -56%, IZAFE-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also offers Pilloxa, a platform that provides real-time insights and improved data quality to empower and motivate patients. The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
iZafe Group reported revenue of kr 6.0M in FY2025 versus kr 442K in FY2021, a compound +91.9%/yr. Reported net income was −kr 16.7M in FY2025.
Is IZAFE-B fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | C$20.93 | C$6.03 | -71% |
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| HOYA Corporation HOCPY | $178.46 | $103.27 | -42% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | $67.81 | $39.78 | -41% |
| ResMed Inc RMD | $196.04 | $185.14 | -6% |
| West Pharmaceutical Services, Inc WST | $330.92 | $114.00 | -66% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $13.07 | $5.51 | -58% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is iZafe Group (IZAFE-B) undervalued?
What is the fair value of IZAFE-B?
What is the quality score of IZAFE-B?
What is the revenue of iZafe Group (IZAFE-B)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full iZafe Group analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.